Related Experiment Video

Updated: Aug 13, 2026

High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay
08:18

High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay

Published on: January 7, 2019

Plasma kinetics of a cholesterol-rich microemulsion in patients submitted to heart transplantation

Camila G Puk1, Carmen G C Vinagre, Edmar Bocchi

  • 1The Heart Institute (InCor) of the Medical School Hospital, University of São Paulo, CEP 05423-000 São Paulo, SP, Brazil.

Transplantation
|October 27, 2004
PubMed

Insights

Heart transplant recipients show impaired low-density lipoprotein (LDL) removal, contributing to hypercholesterolemia and coronary graft disease. This study investigated LDL kinetics in heart transplant (HT) patients to understand these changes.

Area of Science:

  • Cardiology
  • Transplantation Medicine
  • Metabolic Research

Background:

  • Coronary graft disease is a primary cause of late heart transplant failure.
  • Heart transplant recipients often exhibit hypercholesterolemia and altered chylomicron metabolism post-transplant.
  • These metabolic changes may play a role in the development of coronary graft disease.

Purpose of the Study:

  • To investigate if hypercholesterolemia in heart transplant patients is due to reduced low-density lipoprotein (LDL) removal.
  • To assess the plasma kinetics of a cholesterol-rich emulsion that binds to the LDL receptor in heart transplant recipients.

Main Methods:

  • Studied 13 heart transplant (HT) patients and 13 matched healthy controls.
  • Administered an intravenous emulsion labeled with C-cholesteryl oleate.
  • Measured radioactivity decay curves and calculated fractional clearance rates (FCR) over 8 hours.

Main Results:

  • HT patients had significantly higher plasma levels of total cholesterol, LDL cholesterol, HDL cholesterol, and apo B compared to controls.
  • Fractional clearance rate (FCR) of C-cholesteryl oleate was significantly lower in HT patients.

Conclusions:

  • Heart transplant patients demonstrate a deficiency in LDL removal mechanisms.
  • This impaired LDL removal may contribute to the development of coronary graft disease in HT recipients.
Abstract

More Related Videos

Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate11:13

Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate

Published on: May 9, 2019

High-Density Lipoprotein-Specific Phospholipid Efflux Assay07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

Related Concept Videos

Compartment Models: Two-Compartment Model01:20

Compartment Models: Two-Compartment Model

The two-compartment model divides the body into central and peripheral compartments to account for varying blood perfusion rates among organs and tissues, affecting drug distribution. The central compartment includes blood and highly perfused tissues with rapid drug distribution, while the peripheral compartment contains tissues with slower drug distribution. After a single IV bolus dose, the drug concentration is high in plasma and low in tissues. The drug distribution between compartments...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion, mediated...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...